Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies.

ABSTRACT: Immunotherapy drugs have recently been approved by the Food and Drug Administration for the treatment of several genitourinary malignancies, including bladder cancer, renal cancer, and prostate cancer. Preclinical data and early clinical trial results suggest that immune checkpoint inhibitors can act synergistically with radiation therapy to enhance tumor cell killing at local irradiated sites and in some cases at distant sites through an abscopal effect. Because radiation therapy is commonly used in the treatment of genitourinary malignancies, there is great interest in testing the combination of immunotherapy with radiation therapy in these cancers to further improve treatment efficacy. In this review, we discuss the current evidence and biological rationale for combining immunotherapy w

SUBMITTER: Ukleja J 

PROVIDER: S-EPMC8141854 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature